Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

by · The Markets Daily

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,746,822 shares, a growth of 27.5% from the November 30th total of 1,369,590 shares. Based on an average daily volume of 1,900,662 shares, the short-interest ratio is presently 0.9 days. Currently, 11.7% of the company’s stock are sold short. Currently, 11.7% of the company’s stock are sold short. Based on an average daily volume of 1,900,662 shares, the short-interest ratio is presently 0.9 days.

Immix Biopharma Price Performance

Immix Biopharma stock traded down $0.05 during mid-day trading on Thursday, reaching $5.23. 746,279 shares of the company traded hands, compared to its average volume of 1,476,686. The firm’s fifty day moving average is $4.65 and its two-hundred day moving average is $3.19. The company has a market capitalization of $175.62 million, a price-to-earnings ratio of -6.79 and a beta of 0.33. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $7.73.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its earnings results on Friday, November 7th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). As a group, equities research analysts predict that Immix Biopharma will post -0.87 earnings per share for the current year.

Institutional Trading of Immix Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. United Capital Financial Advisors LLC purchased a new position in Immix Biopharma in the third quarter worth approximately $148,000. Velan Capital Investment Management LP lifted its holdings in shares of Immix Biopharma by 40.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after acquiring an additional 10,000 shares during the last quarter. Susquehanna International Group LLP boosted its position in shares of Immix Biopharma by 78.8% during the 3rd quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after purchasing an additional 40,032 shares during the period. Citadel Advisors LLC acquired a new stake in Immix Biopharma in the 3rd quarter valued at approximately $188,000. Finally, Imprint Wealth LLC acquired a new position in Immix Biopharma in the 3rd quarter valued at about $141,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Immix Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Wednesday, October 8th. Finally, HC Wainwright boosted their price target on Immix Biopharma from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Get Our Latest Stock Analysis on Immix Biopharma

About Immix Biopharma

(Get Free Report)

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

See Also